Health industries

For more on the health industries sector, see

Secure your Epic EHR to help mitigate risk and protect patient data webcast - October 27, 2016


During this webcast, PwC’s Enterprise Systems Health Solutions professionals will discuss how to assess security in Epic to help identify and mitigate security and control risks to ultimately maintain compliance and gain greater value out of Epic systems.

HITRUST: Strengthening trust and transparency in the new health economy webcast - September 27, 2016


In this webcast we will discuss the latest developments in the HITRUST framework and how these changes may impact any organization operating along the healthcare continuum.

Pharmaceutical and Life Sciences Tax Quarterly webcast - September 27, 2016


Please join PwC’s Pharmaceutical and Life Sciences practice for a complimentary 90 minute webcast to discuss International Tax Hot Topics.

Patient engagement: Pharma’s strategy for success in the New Health Economy


Pharmaceutical companies are facing new demands from consumers, regulators, insurers and independent groups.

New Markets Tax Credits Program - A Capital Investment Incentive - Webcast replay


In this recorded webcast, our tax professionals discuss key topics related to the New Markets Tax Credit program, including program structure, business eligibility, status of allocation and successful projects.

FASB Stock Compensation Accounting Amendments (ASU 2016-09) Summary of early adopters - Updated August 2016


This study captures the trends of 160 companies identified as early-adopters of the new FASB issued Accounting Standards Update (ASU) 2016-09, Improvements to Employee Share-Based Payment Accounting (the Amendments).

In depth: Pharmaceutical and Life Sciences industry supplement to leasing standard


This supplement to our In depth on leases highlights areas that could create challenges for pharmaceutical and life sciences companies.

US Health Services Deals Insights - Q2 2016 update


US health services deal volume in Q2 2016 increased by approximately 8% from Q1 2016 and 16% on a year-over-year basis. Deal value this quarter increased by nearly 4% compared to Q1 2016, but decreased by 39% when compared to Q2 2015.

Board composition: Pharmaceutical and life sciences industry


Do pharmaceutical and life sciences company directors have the right skills and expertise for the New Health Economy?

Pharmaceutical and Life Sciences Deals Insights Quarterly


We bring you PwC’s perspective on deal activity in the pharmaceutical and life sciences industry. Each quarterly publication now features two sections that highlight deal activity and insights from a global view.